Trade G1 Therapeutics - GTHX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
G1 Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.38 |
Open* | 2.41 |
1-Year Change* | -61.87% |
Day's Range* | 2.41 - 3.18 |
52 wk Range | 1.08-8.40 |
Average Volume (10 days) | 478.73K |
Average Volume (3 months) | 11.23M |
Market Cap | 84.35M |
P/E Ratio | -100.00K |
Shares Outstanding | 51.81M |
Revenue | 77.89M |
EPS | -1.47 |
Dividend (Yield %) | N/A |
Beta | 1.75 |
Next Earnings Date | Feb 28, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 6, 2023 | 2.38 | 0.54 | 29.35% | 1.84 | 2.46 | 1.84 |
Dec 5, 2023 | 1.81 | -0.16 | -8.12% | 1.97 | 1.97 | 1.79 |
Dec 4, 2023 | 1.97 | -0.01 | -0.51% | 1.98 | 2.09 | 1.92 |
Dec 1, 2023 | 1.97 | 0.12 | 6.49% | 1.85 | 1.97 | 1.78 |
Nov 30, 2023 | 1.86 | 0.16 | 9.41% | 1.70 | 1.90 | 1.70 |
Nov 29, 2023 | 1.68 | 0.01 | 0.60% | 1.67 | 1.74 | 1.66 |
Nov 28, 2023 | 1.67 | 0.06 | 3.73% | 1.61 | 1.68 | 1.57 |
Nov 27, 2023 | 1.62 | -0.05 | -2.99% | 1.67 | 1.67 | 1.61 |
Nov 24, 2023 | 1.67 | 0.04 | 2.45% | 1.63 | 1.69 | 1.61 |
Nov 22, 2023 | 1.63 | 0.00 | 0.00% | 1.63 | 1.67 | 1.59 |
Nov 21, 2023 | 1.61 | 0.01 | 0.63% | 1.60 | 1.69 | 1.55 |
Nov 20, 2023 | 1.60 | 0.04 | 2.56% | 1.56 | 1.87 | 1.54 |
Nov 17, 2023 | 1.53 | -0.01 | -0.65% | 1.54 | 1.54 | 1.49 |
Nov 16, 2023 | 1.54 | -0.04 | -2.53% | 1.58 | 1.60 | 1.51 |
Nov 15, 2023 | 1.61 | 0.03 | 1.90% | 1.58 | 1.73 | 1.58 |
Nov 14, 2023 | 1.59 | 0.16 | 11.19% | 1.43 | 1.59 | 1.43 |
Nov 13, 2023 | 1.42 | 0.05 | 3.65% | 1.37 | 1.44 | 1.34 |
Nov 10, 2023 | 1.38 | 0.02 | 1.47% | 1.36 | 1.41 | 1.29 |
Nov 9, 2023 | 1.31 | -0.15 | -10.27% | 1.46 | 1.53 | 1.29 |
Nov 8, 2023 | 1.43 | -0.10 | -6.54% | 1.53 | 1.54 | 1.40 |
G1 Therapeutics Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, February 28, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 G1 Therapeutics Inc Earnings Release Q4 2023 G1 Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 51.301 | 31.476 | 45.285 | 0 | 0 |
Revenue | 51.301 | 31.476 | 45.285 | 0 | 0 |
Total Operating Expense | 187.479 | 173.733 | 141.761 | 129.041 | 89.286 |
Selling/General/Admin. Expenses, Total | 101.033 | 96.491 | 69.445 | 40.648 | 18.603 |
Research & Development | 82.698 | 75.426 | 72.316 | 88.393 | 70.683 |
Operating Income | -136.178 | -142.257 | -96.476 | -129.041 | -89.286 |
Other, Net | 0.003 | -0.546 | -0.542 | 6.594 | 3.998 |
Net Income Before Taxes | -145.859 | -147.427 | -97.844 | -122.447 | -85.288 |
Net Income After Taxes | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
Net Income Before Extra. Items | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
Net Income | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
Total Adjustments to Net Income | 0 | 0 | 0 | ||
Income Available to Common Excl. Extra. Items | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
Income Available to Common Incl. Extra. Items | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
Dilution Adjustment | |||||
Diluted Net Income | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
Diluted Weighted Average Shares | 43.6261 | 41.9434 | 37.878 | 37.4993 | 33.3167 |
Diluted EPS Excluding Extraordinary Items | -3.38235 | -3.53696 | -2.62036 | -3.26532 | -2.55992 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -3.38235 | -3.54005 | -2.62036 | -3.26532 | -2.55992 |
Interest Income (Expense), Net Non-Operating | -9.684 | -4.624 | -0.826 | ||
Cost of Revenue, Total | 3.748 | 2.016 | |||
Gross Profit | 47.553 | 29.46 | |||
Unusual Expense (Income) | -0.2 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 42.392 | 12.946 | 10.25 | 23.576 | 10.573 |
Revenue | 42.392 | 12.946 | 10.25 | 23.576 | 10.573 |
Cost of Revenue, Total | 1.404 | 1.459 | 0.992 | 1.111 | 0.976 |
Gross Profit | 40.988 | 11.487 | 9.258 | 22.465 | 9.597 |
Total Operating Expense | 30.876 | 38.692 | 41.137 | 45.124 | 47.535 |
Selling/General/Admin. Expenses, Total | 17.432 | 21.753 | 23.558 | 24.432 | 25.716 |
Research & Development | 12.04 | 15.48 | 16.587 | 19.581 | 20.843 |
Operating Income | 11.516 | -25.746 | -30.887 | -21.548 | -36.962 |
Interest Income (Expense), Net Non-Operating | -2.067 | -2.373 | -2.518 | -2.553 | -2.357 |
Other, Net | 0.569 | 0.524 | 0.237 | 0.048 | -0.127 |
Net Income Before Taxes | 10.018 | -27.595 | -33.168 | -24.053 | -39.446 |
Net Income After Taxes | 8.71 | -27.595 | -33.649 | -25.272 | -39.446 |
Net Income Before Extra. Items | 8.71 | -27.595 | -33.649 | -25.272 | -39.446 |
Net Income | 8.71 | -27.595 | -33.649 | -25.272 | -39.446 |
Income Available to Common Excl. Extra. Items | 8.71 | -27.595 | -33.649 | -25.272 | -39.446 |
Income Available to Common Incl. Extra. Items | 8.71 | -27.595 | -33.649 | -25.272 | -39.446 |
Diluted Net Income | 8.71 | -27.595 | -33.649 | -25.272 | -39.446 |
Diluted Weighted Average Shares | 61.0405 | 51.6479 | 46.309 | 42.7993 | 42.7077 |
Diluted EPS Excluding Extraordinary Items | 0.14269 | -0.53429 | -0.72662 | -0.59048 | -0.92363 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.14269 | -0.53429 | -0.72662 | -0.59048 | -0.92363 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 179.5 | 243.565 | 216.392 | 271.003 | 370.133 |
Cash and Short Term Investments | 145.07 | 221.186 | 207.306 | 269.208 | 369.29 |
Cash & Equivalents | 94.594 | 221.186 | 207.306 | 269.208 | 369.29 |
Prepaid Expenses | 7.094 | 13.157 | 8.786 | 1.732 | 0.843 |
Total Assets | 187.965 | 254.094 | 228.552 | 284.831 | 371.27 |
Property/Plant/Equipment, Total - Net | 7.951 | 9.048 | 10.508 | 13.391 | 1.137 |
Property/Plant/Equipment, Total - Gross | 9.777 | 10.344 | 11.335 | 14.068 | 1.459 |
Accumulated Depreciation, Total | -1.826 | -1.296 | -0.827 | -0.677 | -0.322 |
Total Current Liabilities | 35.588 | 27.613 | 23.443 | 19.769 | 12.362 |
Accounts Payable | 7.431 | 2.897 | 3.572 | 3.684 | 3.377 |
Accrued Expenses | 26.692 | 24.295 | 17.474 | 16.085 | 8.985 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.465 | 0.421 | 2.397 | ||
Total Liabilities | 119.218 | 110.553 | 51.201 | 29.304 | 12.45 |
Total Long Term Debt | 77.015 | 75.19 | 19.893 | 0 | 0 |
Total Equity | 68.747 | 143.541 | 177.351 | 255.527 | 358.82 |
Redeemable Preferred Stock | |||||
Common Stock | 0.005 | 0.004 | 0.004 | 0.004 | 0.004 |
Retained Earnings (Accumulated Deficit) | -732.018 | -584.459 | -436.107 | -336.853 | -214.406 |
Treasury Stock - Common | -0.008 | -0.008 | -0.008 | -0.008 | -0.008 |
Total Liabilities & Shareholders’ Equity | 187.965 | 254.094 | 228.552 | 284.831 | 371.27 |
Total Common Shares Outstanding | 51.4994 | 42.5621 | 38.1141 | 37.6116 | 37.2421 |
Other Liabilities, Total | 6.615 | 7.75 | 7.865 | 9.535 | 0.088 |
Additional Paid-In Capital | 800.768 | 728.004 | 613.462 | 592.384 | 573.23 |
Other Current Assets, Total | 0.063 | 0.063 | 0.063 | 0.063 | |
Other Long Term Assets, Total | 0.514 | 1.481 | 1.652 | 0.437 | |
Total Receivables, Net | 11.094 | 5.688 | 0.237 | ||
Accounts Receivable - Trade, Net | 11.094 | 5.688 | 0.237 | ||
Long Term Debt | 77.015 | 75.19 | 19.893 | ||
Total Inventory | 16.179 | 3.471 | |||
Short Term Investments | 50.476 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 126.103 | 140.436 | 153.965 | 179.5 | 157.465 |
Cash and Short Term Investments | 94.352 | 104.231 | 116.317 | 145.07 | 122.982 |
Cash & Equivalents | 52.623 | 55.914 | 68.237 | 94.594 | 93.238 |
Total Receivables, Net | 9.265 | 13.171 | 16.025 | 11.094 | 10.521 |
Accounts Receivable - Trade, Net | 9.265 | 13.171 | 16.025 | 11.094 | 10.521 |
Total Inventory | 13.491 | 15.6 | 15.543 | 16.179 | 13.95 |
Prepaid Expenses | 8.932 | 7.371 | 6.017 | 7.094 | 9.949 |
Other Current Assets, Total | 0.063 | 0.063 | 0.063 | 0.063 | 0.063 |
Total Assets | 133.097 | 147.891 | 161.957 | 187.965 | 166.573 |
Property/Plant/Equipment, Total - Net | 6.78 | 7.173 | 7.564 | 7.951 | 8.365 |
Property/Plant/Equipment, Total - Gross | 8.995 | 9.261 | 9.522 | 9.777 | 10.054 |
Accumulated Depreciation, Total | -2.215 | -2.088 | -1.958 | -1.826 | -1.689 |
Other Long Term Assets, Total | 0.214 | 0.282 | 0.428 | 0.514 | 0.743 |
Total Current Liabilities | 33.653 | 33.912 | 33.69 | 35.588 | 37.134 |
Accounts Payable | 7.335 | 5.762 | 5.38 | 7.431 | 8.442 |
Accrued Expenses | 24.181 | 24.681 | 22.767 | 26.692 | 27.251 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.137 | 3.469 | 5.543 | 1.465 | 1.441 |
Total Liabilities | 90.075 | 90.343 | 116.969 | 119.218 | 120.608 |
Total Long Term Debt | 51.246 | 50.936 | 77.47 | 77.015 | 76.558 |
Long Term Debt | 51.246 | 50.936 | 77.47 | 77.015 | 76.558 |
Other Liabilities, Total | 5.176 | 5.495 | 5.809 | 6.615 | 6.916 |
Total Equity | 43.022 | 57.548 | 44.988 | 68.747 | 45.965 |
Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.004 |
Additional Paid-In Capital | 812.132 | 808.454 | 804.604 | 800.768 | 744.338 |
Retained Earnings (Accumulated Deficit) | -769.107 | -750.903 | -759.613 | -732.018 | -698.369 |
Treasury Stock - Common | -0.008 | -0.008 | -0.008 | -0.008 | -0.008 |
Total Liabilities & Shareholders’ Equity | 133.097 | 147.891 | 161.957 | 187.965 | 166.573 |
Total Common Shares Outstanding | 51.8099 | 51.7085 | 51.6593 | 51.4994 | 42.8971 |
Short Term Investments | 41.729 | 48.317 | 48.08 | 50.476 | 29.744 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -147.559 | -148.352 | -99.254 | -122.447 | -85.288 |
Cash From Operating Activities | -128.62 | -132.108 | -83.742 | -99.571 | -74.307 |
Cash From Operating Activities | 0.53 | 0.469 | 0.582 | 0.356 | 0.175 |
Non-Cash Items | 23.716 | 24.613 | 19.006 | 16.449 | 10.233 |
Changes in Working Capital | -5.307 | -8.838 | -4.076 | 6.071 | 0.573 |
Cash From Investing Activities | -50.529 | 0 | 0.152 | -2.716 | -0.709 |
Capital Expenditures | -0.506 | 0 | -2.716 | -0.709 | |
Cash From Financing Activities | 52.495 | 145.863 | 21.688 | 2.705 | 340.494 |
Financing Cash Flow Items | -0.043 | -1.411 | -0.62 | 0 | -0.892 |
Issuance (Retirement) of Stock, Net | 52.538 | 92.274 | 2.308 | 2.705 | 341.386 |
Net Change in Cash | -126.654 | 13.755 | -61.902 | -99.582 | 265.478 |
Cash Interest Paid | 7.924 | 2.908 | 0.997 | ||
Other Investing Cash Flow Items, Total | -50.023 | 0 | 0.152 | ||
Issuance (Retirement) of Debt, Net | 0 | 55 | 20 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -27.595 | -147.559 | -113.91 | -88.638 | -49.192 |
Cash From Operating Activities | -29.053 | -128.62 | -97.988 | -76.741 | -38.184 |
Cash From Operating Activities | 0.132 | 0.53 | 0.393 | 0.254 | 0.115 |
Non-Cash Items | 4.75 | 23.716 | 18.876 | 13.433 | 7.071 |
Cash Interest Paid | 2.512 | 7.924 | 5.61 | 3.537 | 1.716 |
Changes in Working Capital | -6.34 | -5.307 | -3.347 | -1.79 | 3.822 |
Cash From Investing Activities | 2.91 | -50.529 | -30.167 | -0.506 | 0 |
Capital Expenditures | -0.506 | -0.506 | -0.506 | ||
Cash From Financing Activities | -0.214 | 52.495 | 0.145 | 0.018 | 0.018 |
Financing Cash Flow Items | -0.215 | -0.043 | 0 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 0.001 | 52.538 | 0.145 | 0.018 | 0.018 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Net Change in Cash | -26.357 | -126.654 | -128.01 | -77.229 | -38.166 |
Other Investing Cash Flow Items, Total | 2.91 | -50.023 | -29.661 | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Eshelman Ventures LLC | Corporation | 8.7275 | 4516074 | 1076923 | 2023-03-31 | |
MedImmune Ventures, Inc. | Venture Capital | 5.7022 | 2950630 | 0 | 2023-03-31 | LOW |
Fisher Investments | Investment Advisor/Hedge Fund | 4.9144 | 2543006 | -181704 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.7686 | 1950068 | -29660 | 2023-06-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 3.5172 | 1820015 | -29832 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.1624 | 1118965 | -57089 | 2023-06-30 | LOW |
Raymond James & Associates, Inc. | Research Firm | 1.7891 | 925776 | 133662 | 2023-09-30 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 1.1914 | 616503 | 186864 | 2023-06-30 | MED |
Millennium Management LLC | Hedge Fund | 1.1751 | 608065 | -267069 | 2023-06-30 | HIGH |
Renaissance Technologies LLC | Hedge Fund | 1.105 | 571791 | 128816 | 2023-06-30 | HIGH |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 0.9523 | 492776 | 209541 | 2023-06-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8342 | 431652 | -6742 | 2023-06-30 | LOW |
Tekla Capital Management LLC | Investment Advisor | 0.8191 | 423869 | 0 | 2023-06-30 | LOW |
BofA Global Research (US) | Research Firm | 0.6191 | 320346 | -283072 | 2023-06-30 | LOW |
GSA Capital Partners LLP | Hedge Fund | 0.5141 | 266017 | 266017 | 2023-06-30 | HIGH |
Bailey (John E JR) | Individual Investor | 0.4778 | 247252 | -2719 | 2023-07-05 | MED |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.4631 | 239609 | 35245 | 2023-06-30 | LOW |
Needham Investment Management L.L.C. | Investment Advisor/Hedge Fund | 0.4522 | 234000 | 0 | 2023-06-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.4362 | 225700 | 225700 | 2022-12-31 | LOW |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.4294 | 222182 | -133 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
G1 Therapeutics Company profile
About G1 Therapeutics Inc
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The Company's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, G1 Therapeutics Inc revenues decreased 30% to $31.5M. Net loss increased 49% to $148.4M. Revenues reflect License revenue decrease of 55% to $20.4M. Higher net loss reflects General and Administrative - Balancing increase of 40% to $77.6M (expense), Stock-based Compensation in SGA increase of 45% to $17.3M (expense), Research & Development - Balancing value increase of 8% to $70.6M (expense).
Industry: | Bio Therapeutic Drugs |
700 Park Offices Drive
Suite 200
RESEARCH TRIANGLE PARK
NORTH CAROLINA 27709
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com